Status:

TERMINATED

Reducing Insulin, Growth Hormones, and Tumors

Lead Sponsor:

Fred Hutchinson Cancer Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Diet Modification

Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The objective of this project is to compare the effect of two widely implemented cancer diets, differing drastically in macronutrient content, on biomarkers of inflammation, compared to a control diet...

Detailed Description

Little is known about the role of diet in the treatment of lung and other cancers, yet physicians are constantly confronted with the question 'what should I eat' by their patients. Very few randomized...

Eligibility Criteria

Inclusion

  • Adults (18 years or older) receiving treatment at the Seattle Cancer Care Alliance (SCCA)
  • Stage IIIB and IV non-small cell adenocarcinoma or squamous cell carcinoma, or small cell lung cancer with advanced disease receiving therapy with systemic treatment
  • Body mass index (BMI) \>= 20 kg/m\^2
  • Body weight within 10% of current weight within the 3 months before starting the study
  • Able and willing to attend bi-weekly dietary support sessions at the Seattle Cancer Care Alliance (SCCA) during the initial 12-week intervention period
  • Willing and able to follow the dietary regimen
  • Willing to maintain usual lifestyle habits (other than diet) throughout the study (e.g., physical activity habits)
  • Ability to understand, speak, and write in English
  • Ability to provide informed written consent

Exclusion

  • Neuroendocrine large cell carcinoma or atypical carcinoids with metastatic disease
  • Small cell lung cancer receiving curative therapy with radiation
  • Use of antidiabetic medications or insulin within the last 6 months
  • Presence of grade 2 weight loss, cachexia, and/or severe nausea
  • Current participation in therapeutic first line trial
  • Alcohol intake \> 2 drinks per day
  • Major dietary restriction, as determined by the researcher
  • Other significant health condition as determined by the researcher

Key Trial Info

Start Date :

December 21 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 5 2019

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT03785808

Start Date

December 21 2018

End Date

August 5 2019

Last Update

August 12 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Seattle Cancer Center Alliance

Seattle, Washington, United States, 98109